Norfolk, VANCT04436081Now EnrollingIRB Ready

Alzheimer Disease Clinical Trial in Norfolk, VA

Access cutting-edge alzheimer disease treatment through this phase 2 clinical trial at a research site in Norfolk. Study-provided care at no cost to qualified participants.

Sponsored by Eastern Virginia Medical School

Quick Self-Assessment

See if you qualify for this Norfolk location

Preparing your pre-screening questions…

Expert Care in Norfolk

Access alzheimer disease specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related alzheimer disease treatment provided free

Apply for This Norfolk Location

Check if you qualify for this alzheimer disease clinical trial in Norfolk, VA

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Norfolk

    Convenient for VA residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Norfolk site if eligible
  4. 4Begin participation

About This Alzheimer Disease Study in Norfolk

This is a randomized, double-blinded, placebo-controlled, crossover trial that aims to 1) determine the efficacy of THC-free cannabidiol (CBD oil) in reducing the severity of agitation among participants and 2) determine whether THC-free CBD oil can reduce the burden on caregivers and increase the participants' quality of life.

Sponsor: Eastern Virginia Medical School

Who Can Participate

Inclusion Criteria

Males/females over 50 years old.
Have a diagnosis of dementia due to AD or mixed AD with another type of dementia.
A Mini-Mental State Exam score (MMSE) between 4 and 28 inclusive.
Presence of agitation with a Neuropsychiatric Inventory (NPI)-agitation/aggression subscore \> 3.
Participants and their informal caregivers must be fluent in English (includes reading, writing, and speech) and able to give informed consent.
For patients treated with cognitive-enhancing medications (cholinesterase inhibitors (ChEI) and/or memantine), the dosage must be stable for at least 1 month (30 days). If the ChEI and/or memantine has been discontinued, patients may enroll after 15 days.
Eligible caregivers must either live with the participant or have a minimum of 4 hours of daily contact with them.

Exclusion Criteria

Diagnosis of non-AD or non-mixed dementias.
Very mild dementia or advanced dementia (MMSE: greater than 28 or less than 4).
NPI-agitation-aggression score \< 3.
Having a serious or unstable medical illness including cardiovascular, hepatic, renal, respiratory, endocrine, neurologic or hematologic disease which might confound assessment of safety outcomes as determined by the study physician.
Presence or history of other serious psychiatric disorders or neurological conditions (e.g. psychotic disorders, bipolar disorder or schizophrenia).
Current abuse of/dependence on marijuana, current drug abuse, current alcohol abuse.
Having seizure disorders.
Pregnant or breastfeeding
Indication of baseline delirium as determined by the Confusion Assessment Method (CAM).
Current use of lithium.
Inability to swallow CBD oil softgels.
Changes in dosage of anti-depressives within 4 weeks before randomization and during the study.
Changes in dosage of antipsychotics or benzodiazepines within 1 week prior to randomization and during the study.
Contraindications to CBD oil (history of hypersensitivity to any cannabinoid).
Frequent falling due to orthostatic hypotension.
Use of tricyclic antidepressants (TCA), fluoxetine, and/or carbamazepine. -Patients who reside in nursing homes.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Norfolk?

Yes, this clinical trial (NCT04436081) has an active research site in Norfolk, VA that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Alzheimer Disease Treatment Options in Norfolk, VA

If you're searching for alzheimer disease treatment options in Norfolk, VA, this clinical trial (NCT04436081) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Norfolk research site is actively enrolling participants for this phase 2 clinical trial. You'll receive care from experienced alzheimer disease specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all alzheimer disease clinical trials near you to find additional studies recruiting in your area.

More Alzheimers Disease Trials in Norfolk, VA

See all alzheimers disease clinical trials recruiting in Norfolk — not just this study.

Browse Alzheimers Disease Trials in Norfolk →

Ready to Join in Norfolk?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Norfolk, VA